. Author manuscript; available in PMC: 2021 Jul 2.

Published in final edited form as: Eur Urol Oncol. 2018 Jun 13;1(5):364–377. doi: 10.1016/j.euo.2018.04.015

Table 3 –

Difference in selected GAG properties between RCC (n = 116) and healthy samples (n = 44) from the discovery set (across three cohorts) according to Bayesian estimation

GAG property	MD (95% HDI)	Effective MCMC samples	MCMC samples in ROPE (%) ^a
6s CS	1.59 (0.92–2.29)	23 010	0.01
6s/(4s + 6s) CS	0.08 (0.06–0.10)	22 228	0.03
CS_tot	6.04 (1.80–7.78)	19 045	0.02
CS charge	0.13 (0.11–0.16)	11 857	0.00
$\log_{2} (\frac{0 s}{Ns + 0 s} HS)$	0.12 (0.04–0.22)	13 189	2.35

GAG = glycosaminoglycan; RCC = renal cell carcinoma; MD = modal difference between RCC and healthy samples; HDI = high-density interval; MCMC = Markov chain Monte Carlo; ROPE = region of practical equivalence; CS = chondroitin sulfate; HS = heparan sulfate.

Differences for which the fraction of MCMC samples in ROPE was below 5% are considered statistically significant.